CBIO

Catalyst Biosciences

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$102.9M

Burn Rate (Qtr)

$16.0M

Company Profile

Catalyst Biosciences is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hemostasis and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (“AMD”). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

SQ Marzeptacog alfa “MarzAA”

Hemophilia A or B w Inhibitors - ToB

Phase 3 Initiation

2020

SQ Dalcinonacog alfa “DalcA”

Hemophilia B (rFIX)

Phase 2 Data

TBD

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon